For All The Latest Medical News, Health News, Research News, COVID-19 News, Dengue News, Glaucoma News, Diabetes News, Herb News, Phytochemical News, Cardiology News, Epigenetic News, Cancer News, Doctor News, Hospital News

BREAKING NEWS
Source: Thailand Medical News  Nov 23, 2019  5 years, 1 month, 9 hours, 23 minutes ago

Study Confirms Suvorexant As A Better Drug For Insomnia Treatment

Study Confirms Suvorexant As A Better Drug For Insomnia Treatment
Source: Thailand Medical News  Nov 23, 2019  5 years, 1 month, 9 hours, 23 minutes ago
Typically, a class of drugs known as hypnotics are traditionally used to treat Insomnia which is one of the most common sleep disorders. However, usage of  hypnotics come with motor and cognitive side effects. A  new study conducted by researchers from the University of Tsukuba in Japan, show that  Suvorexant, (trade name : Belsomra)  which is a recently approved and is a more targeted treatment, has fewer physical side effects.


 
Common hypnotic agents for the treatment of insomnia are γ-aminobutyric acid (GABA) agonists, which bind to GABAA receptors to enhance the action of the inhibitory neurotransmitter, GABA. GABAA receptors are widespread, which means that GABA agonists inhibit neurons throughout the brain and spinal cord, including those that are not involved in sleep.
 
This is not the case for suvorexant, which was approved as a treatment for insomnia in the U.S. and Japan in 2014. According to the new study published in PNAS on November 11, 2019,  suvorexant has a good efficacy and fewer side effects.


 
Dr Jaehoon Seol, first author of the study told Thailand Medical News, "One concern about the use of GABA agonists is their side effects as they might impair the normal ability to respond to unexpected stimuli during sleep in urgent situations. A drug that specifically acts on brain receptors involved in wakefulness, rather than the whole brain, could avoid this."
 
Belsomra or Suvorexant inhibits orexin receptors of the wake-promoting system, thus inhibiting wakefulness. This makes it a more targeted treatment than GABA agonists. To study whether this would result in less severe side effects, the researchers conducted a randomized controlled trial with 30 healthy men in a sleep lab. Participants took either suvorexant, brotizolam (a GABA agonist), or a placebo before falling asleep and were then woken up 90 minutes later. Their cognitive and physical functioning was then tested.
 
Suvorexant (Belsomra)  induced fewer impairments in body balance upon awakening than brotizolam. This could be associated with the cerebellum, a part of the brain that coordinates balance. Namely, the cerebellum contains GABAA receptors but not orexin receptors. In this case, brotizolam may have affected cerebellar functioning, while suvorexant did not.
 
Dr Masashi Yanagisawa, lead author of the study also commented to Thailand Medical News, "This is the first study to investigate the potential side effects of suvorexant and to compare these with those of brotizolam. Also, suvorexant was just as effective as brotizolam in the treatment of&l t;strong> insomnia, with comparable effects on sleep duration and efficiency."
 
Globally, as there is a reported prevalence of 10-40 percent, insomnia is now considered a serious health issue. These new findings are potentially significant and could lead to further large-scale studies in patients with insomnia.
 
Reference: Jaehoon Seol et al. Distinct effects of orexin receptor antagonist and GABAA agonist on sleep and physical/cognitive functions after forced awakening, Proceedings of the National Academy of Sciences (2019). DOI: 10.1073/pnas.1907354116

MOST READ

Nov 26, 2024  27 days ago
Nikhil Prasad
Nov 19, 2024  1 month ago
Nikhil Prasad
Nov 05, 2024  2 months ago
Nikhil Prasad
Nov 05, 2024  2 months ago
Nikhil Prasad
Jul 25, 2024  5 months ago
Nikhil Prasad
Jul 24, 2024  5 months ago
Nikhil Prasad
Jun 10, 2023  2 years ago
COVID-19 News - DNA Methylation - Asymptomatic SARS-CoV-2 Infections
Aug 04, 2022  2 years ago
Source: Medical News - SARS-CoV-2 & Cancer